SAFETY SUBGROUP ANALYSES FROM THE CECOG PHASE III TURANDOT TRIAL: FIRST-LINE BEVACIZUMAB (BEV) IN COMBINATION WITH CAPECITABINE (X) OR PACLITAXEL (P) FOR HER2-NEGATIVE LOCALLY RECURRENT OR METASTATIC BREAST CANCER (LR/MBC)

被引：0
|
作者：
Lang, I. [1 ]
Inbar, M. [2 ]
Greil, R. [3 ]
Kahan, Z. [4 ]
Beslija, S. [5 ]
Steger, G. G. [6 ]
Stemmer, S. M. [7 ]
Zvribule, Z. [8 ]
Kaufman, B. [9 ]
Zielinski, C. [10 ,11 ]
机构：
[1] Natl Inst Oncol, Dept Med Oncol & Clin Pharmacol B, Budapest, Hungary
[2] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel
[3] Med Univ Salzburg, Dept Med, Salzburg, Austria
[4] Univ Med Sch Szeged, Szeged, Hungary
[5] Inst Oncol, Sarajevo, Bosnia & Herceg
[6] Med Univ Vienna, Med & Canc Ctr, Vienna, Austria
[7] Davidoff Ctr, Petah Tiqwa, Israel
[8] Riga Eastern Hosp, Latvian Ctr Oncol, Riga, Latvia
[9] Chaim Sheba Med Ctr, Div Oncol, Ramat Gan, Israel
[10] Univ Hosp, Dept Med 1, Vienna, Austria
[11] Ctr Canc, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：98 / 98
页数：1
相关论文
共 50 条
  • [1] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
    Lang, I.
    Inbar, M.
    Steger, G.
    Greil, R.
    Zvirbule, Z.
    Beslija, S.
    Kahan, Z.
    Taskova, V.
    Kaufmann, B.
    Zielinski, C. C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 278
  • [2] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line chemotherapy (CT) for HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC): Preliminary safety data from the CECOG phase III TURANDOT trial.
    Lang, I.
    Inbar, M. J.
    Greil, R.
    Steger, G. G.
    Beslija, S.
    Kahan, Z.
    Eniu, A. E.
    Zvirbule, Z.
    Sirbu, D. E.
    Zielinski, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
    Lang, I.
    Inbar, M. J.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G. G.
    Messinger, D.
    Brodowicz, T.
    Zielinski, C.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (17) : 3140 - 3149
  • [4] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
  • [5] Randomized Phase III Study of First-line Bevacizumab in Combination With Capecitabine or Paclitaxel for HER2-negative LR/MBC: Interim Safety Data
    Inbar, M.
    Lang, I.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G. G.
    Zielinski, C. C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S346 - S346
  • [6] Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
    Lam, Siu W.
    Nota, Nienke M.
    de Groot, Steffen M.
    Jager, Agnes
    Bos, Monique M. E. M.
    Linn, Sabine C.
    van den Bosch, Joan
    Braun, Hans J.
    van der Velden, Ankie M. T.
    Los, Maartje
    Portielje, Johanneke E. A.
    Kroep, Judith R.
    Honkoop, Aafke H.
    Smorenburg, Carolien H.
    Tanis, Bea
    van Riel, Johanna M. G. H.
    Terwogt, Jetske M. Meerum
    den Boer, Marien O.
    Douma, Joep
    Jeurissen, Frank
    Berends, Johan
    van Tinteren, Harm
    Boven, Epie
    CANCER RESEARCH, 2015, 75
  • [7] Subgroup efficacy analyses of the randomized phase III TANIA trial evaluating continued or reintroduced bevacizumab (BEV) after 1st-line BEV for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Puglisi, Fabio
    Cortes, Javier
    Vrdoljak, Eduard
    Gligorov, Joseph
    Marschner, Norbert
    Zielinski, Christoph
    de Laurentiis, Michele
    Brain, Etienne
    Levy, Christelle
    Welt, Anja
    Kahan, Zsuzsanna
    Inbar, Moshe
    de Ducla, Sabine
    Freudensprung, Ulrich
    von Minckwitz, Gunter
    CANCER RESEARCH, 2015, 75
  • [8] FIRST EFFICACY RESULTS FROM THE TURANDOT PHASE III TRIAL COMPARING TWO BEVACIZUMAB (BEV)-CONTAINING REGIMENS AS FIRST-LINE THERAPY FOR HER2-NEGATIVE METASTATIC BREAST CANCER (MBC)
    Zielinski, C.
    Lang, I.
    Inbar, M.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Zvirbule, Z.
    Steger, G.
    Melichar, B.
    Pienkowski, T.
    Sirbu, D.
    Petruzelka, L.
    Eniu, A.
    Nisenbaum, B.
    Dank, M.
    Anghel, R.
    Messinger, D.
    Brodowicz, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 116 - 116
  • [9] Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Zielinski, C. C.
    Lang, I.
    Inbar, M.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Zvirbule, Z.
    Steger, G. G.
    Melichar, B.
    Pienkowski, T.
    Sirbu, D.
    Petruzelka, L.
    Eniu, A.
    Nisenbaum, B.
    Dank, M.
    Anghel, R.
    Messinger, D.
    Brodowicz, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S263 - S264
  • [10] Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
    Brodowicz, T.
    Pienkowski, T.
    Beslija, S.
    Melichar, B.
    Lang, I.
    Inbar, M. J.
    Anghel, R.
    Spanik, S.
    Ahlers, S.
    Zielinski, C.
    CANCER RESEARCH, 2013, 73
12345